MedCity News
FEBRUARY 28, 2025
The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.
Fierce Pharma
NOVEMBER 5, 2024
works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. As the U.K. Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 21, 2023
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.
MedCity News
FEBRUARY 19, 2025
We’re looking for biopharma startups focused on infectious diseases, medtech/diagnostics startups supporting chronic disease management, and health tech startups seeking to improve care navigation and coordination and developing AI tech.
MedCity News
JANUARY 25, 2024
Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.
MedCity News
FEBRUARY 16, 2024
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
MedCity News
MAY 25, 2023
The competition saw 23 healthcare startups across biopharma, medical devices, and health tech geared for consumers/employers as well as payers/providers pitch their business plans to teams of investor judges.
Expert insights. Personalized for you.
258 
Let's personalize your content